Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

This study is testing a drug called linperlisib (a PI3K inhibitor that blocks a growth pathway in cancer cells) in combination with immunotherapy and chemotherapy for people with large B-cell lymphoma that has returned or stopped responding to first-line treatment. **You may be eligible if...** - You have confirmed large B-cell lymphoma (a type of blood cancer) that has relapsed or stopped responding to first-line therapy - Your first-line treatment included anti-CD20 antibody (like rituximab) and anthracycline chemotherapy - You are otherwise eligible for further treatment **You may NOT be eligible if...** - You have already received more than one prior line of therapy for relapsed/refractory disease - You have received prior treatment that included this type of drug (PI3K inhibitor) - You have active infections or significant organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.